American Marconi Wireless News - Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events

The expanded agreement includes long-form televised interviews, earned media placements, national TV commercials, and participation in exclusive AccreditedEvents.com investor forums. Through this collaboration, Acurx will continue to showcase its innovation and growth trajectory to millions of viewers and investors worldwide.

Strategic Media Partnership

The renewed partnership will bring Acurx to audiences across Bloomberg Television and Fox Business (as sponsored programming), New to The Street's 3.4M+ subscriber YouTube channel, iconic outdoor billboards in New York City's Times Square and Financial District, and social platforms including LinkedIn, X, Facebook, and Instagram.

Additionally, participation in AccreditedEvents.com will provide Acurx with direct access to targeted, qualified, and accredited investors through exclusive in-person and virtual events, further deepening the company's engagement with the investment community.

Executive Commentary

Vince Caruso, CEO & Co-Founder of New to The Street, stated: "We are proud to continue showcasing Acurx's pioneering work in antibiotic development. Our multi-platform approach - spanning national TV broadcasts, digital distribution, iconic outdoor billboards, and exclusive investor events - ensures predictable media exposure and helps companies like Acurx strengthen their visibility within the biotech investment community."

About Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP), and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).

Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year subject to obtaining appropriate financing. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.

About New to The Street

For more than 16 years, New to The Street has been one of the longest-running U.S. and international sponsored and syndicated Nielsen-rated television programs, broadcasting weekly on Fox Business and Bloomberg Television as sponsored programming. With over 3.4 million YouTube subscribers, 500,000+ combined social followers, and iconic outdoor billboards in Times Square and New York City's Financial District, New to The Street provides companies with Predictable Media™ - a unique blend of long-form interviews, commercials, social media amplification, earned media pickups, and accredited investor access.
For more information, visit: www.newtothestreet.com.

Media Contact:
Monica Brennan
New to The Street
[email protected]

SOURCE: New to The Street

View the original press release on ACCESS Newswire

G.Stevens--AMWN